Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.
* denotes publications from the CTD2 initiative that are results of intra-Network collaborations
UCSF (1) CTD2 scientists developed a quantitative chemoproteomics approach that combines kinase affinity capture with quantitative mass spectrometry. This technique could be used for developing effective combinatorial therapies.
CTD2 sceintists at Columbia University developed a new precision oncology approach, OncoTreat. This approach enables the systematic prioritization of compounds targeting tumor checkpoint dependencies in gastroenteropancreatic neuroendocrine tumors.
Authors identified transcription factor activating protein 4 (TFAP4) as a critical effector of MYCN amplification in neuroblastoma and showed that silencing TFAP4 inhibits MYCN-amplified neuroblastoma cell growth.
CTD2 scientists at UCSF showed that tumor progression and dissemination are governed by evolutionary selection pressures that operate at a multicellular level and differ from the clonal events that drive initiation and the benign-malignant transition.